Everest Re Group, Ltd.

(New York Stock Exchange)
Back to all articles
Bullish +75

LENZ Therapeutics, Inc.: LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ (LNZ100) in Greater China

AI-generated analysis

🀝 Everest Medicines acquires exclusive rights from Corxel to develop and commercialize LENZ Therapeutics' VIZZ (LNZ100) eye drop in Greater China.

πŸ“… NDA for LNZ100 submitted to Chinese regulators in September 2025 with approval expected in Q1 2027.

πŸ’° LENZ eligible for up to $85.0 million in regulatory and sales milestones plus tiered royalties on net sales.

πŸ‘οΈ VIZZ is the first and only FDA-approved aceclidine-based eye drop for treating presbyopia, a condition affecting 1.8 billion people globally.

🌏 Agreement covers Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan regions.

πŸ—£οΈ Everest Medicines Chairman Yifang Wu calls LNZ100 a differentiated asset with meaningful clinical value and strong commercial potential.

πŸš€ LENZ CEO Eef Schimmelpennink describes the deal as providing a transformative new treatment option for millions of adults.

πŸ“ˆ Everest leverages its fully integrated commercialization platform to accelerate product lifecycle management in Asia.

Bullish Signals
  • Acquisition of Greater China rights expands LENZ Therapeutics' international footprint into a high-growth market for presbyopia treatments.
  • Up to $85.0 million in potential milestone payments provides significant near-term financial upside for the company.
  • VIZZ is already FDA-approved and has demonstrated clinical value, reducing regulatory risk in the new territory.
  • Tiered royalty structure ensures ongoing revenue participation based on commercial success in Greater China.
  • Partnership with Everest Medicines leverages their deep expertise and established commercialization platform in Asia.
  • Presbyopia patient population is growing globally, creating significant unmet medical need for non-invasive treatments.
Risk Factors
  • Forward-looking statements regarding approval and commercialization are subject to substantial risks and uncertainties including regulatory delays.
  • Royalty rates are tiered and mid-single-digit to low-double-digit, which may be lower than upfront licensing fees for other assets.
Full Analysis
LENZ Therapeutics, Inc. (Nasdaq: LENZ) announced that Everest Medicines has acquired rights to develop and commercialize VIZZ (LNZ100), an aceclidine-based eye drop for presbyopia, in Greater China. This includes the Chinese mainland, Hong Kong SAR, Macao SAR, and Taiwan. The agreement involves the transfer of rights and obligations from Corxel Pharmaceuticals, which previously held the license. The New Drug Application (NDA) for LNZ100 was submitted to China's National Medical Products Administration in September 2025, with regulatory approval anticipated in the first quarter of 2027. Under the deal, LENZ is eligible to receive up to $85.0 million in remaining regulatory and sales milestones, plus tiered royalties ranging from mid-single-digit to low-double-digit percentages on net sales. LENZ CEO Eef Schimmelpennink highlighted the partnership as a transformative step for millions of adults with presbyopia, noting that VIZZ is already FDA-approved in the US. Everest Medicines Chairman Yifang Wu described LNZ100 as a differentiated asset with strong commercial potential in a growing patient population seeking non-invasive treatment options. LENZ Therapeutics is headquartered in San Diego, California, and focuses on global licensing partnerships to expand access to VIZZ. The company views this acquisition as a key part of its international expansion strategy, leveraging Everest's established commercialization platform in the Asian market.